- •This cost analysis focused on physician prescribing practices rather than the drugs themselves.
- •Physicians using botulinum toxin predominantly for spasticity were included.
- •A majority of physicians exclusively used the costliest drug, onabotulinumtoxinA.
- •Those prescribing abobotulinumtoxinA or incobotulinumtoxinA had lower cost per patient.
- •Doses and injections per year were not significantly different between groups.
Main Outcome Measure
List of abbreviations:BoNT-A (Botulinum toxin type A), CMS (Centers for Medicare & Medicaid Services), CPT (current procedural terminology), OOP (out of pocket)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Archives of Physical Medicine and Rehabilitation
Centers for Medicare & Medicaid Services. Available at:https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/ForecastSummary.pdf. Accessed May 1, 2020.
- Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.Am J Health Syst Pharm. 2015; 72: 301-307
- Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom.Clinicoecon Outcomes Res. 2015; 7: 185-193
- Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.J Manag Care Spec Pharm. 2021; 27: 478-487
- Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology.Neurology. 2016; 86: 1818-1826
Centers for Medicare & Medicaid Services, Medicare provider utilization and payment data: physician and other supplier. Available at:https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Physician-and-Other-Supplier. Accessed February 1, 2021.
- Conversion Ratio between Botox®, Dysport®, and Xeomin® in clinical practice.Toxins (Basel). 2016; 8: 65
Centers for Medicare & Medicaid Services, Medicare part B discarded drug units report. Available at: https://www.cms.gov/research-statistics-data-systems/cms-drug-spending/medicare-part-b-discarded-drug-units-report. Accessed February 1, 2021.
- A systematic review of the incidence, prevalence, costs, and activity and work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 update.Arch Phys Med Rehabil. 2021; 102: 115-131
- Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event.Stroke. 2010; 41: 319-324
- Value-based physician reimbursement: challenges and opportunities for physical medicine and rehabilitation.PM R. 2009; 1: 706-708
- Evidence to practice: botulinum toxin in the treatment of spasticity post stroke.Top Stroke Rehabil. 2012; 19: 115-121
- Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study.J Neurol. 2011; 258: 1670-1675
- Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries.Med Devices (Auckl). 2012; 5: 97-101
- Real-world six-year national cost-minimization analysis of incobotulinumtoxinA and onabotulinumtoxinA in the VA/DoD healthcare systems.Clinicoecon Outcomes Res. 2021; 13: 603-609
- A retrospective cost analysis of patients who switched from onabotulinumtoxinA to incobotulinumtoxinA in a private neurology practice.Am Health Drug Benefits. 2020; 13: 205-210
Disclosures: R Kazerooni was an employee of Merz Pharmaceuticals, LLC at the time of this analysis. M Verduzco-Gutierrez participated on speaker's bureaus and advisory boards for Merz, Allergan, Ipsen, and Medtronic. The other authors have nothing to disclose.